Akut mieloid leukémia (AML): vizsgálatok itt: Magyarország
7 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 15.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleStudies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Where
- Budapest IX, Debrecen, Győr, Kaposvár, Nyíregyháza
- Életkor
- 18 év and over
- People
- 1300 worldwide
- Run by
- Kura Oncology, Inc.
See details and how to joinNCT07007312 · EU 2025-521314-25-00 - 3. fázisTaking peopleA Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Where
- Budapest, Debrecen, Győr, Pécs, Szeged
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06852222 · EU 2024-520154-38-00 - 3. fázisTaking peopleStudy of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
- Where
- Budapest VIII, Debrecen, Győr, Szekszárd
- Életkor
- 12 év and over
- People
- 468 worldwide
- Run by
- Syndax Pharmaceuticals
See details and how to joinNCT07211958 · EU 2025-522279-27-00 - 2/3. fázisTaking peopleA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Where
- Budapest VIII, Debrecen, Győr, Szeged
- Életkor
- 18 év and over
- People
- 316 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04256317 · EU 2024-515098-93-00 - 2. fázisTaking peopleA Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)
- Where
- Debrecen
- Életkor
- 18 év and over
- People
- 332 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT04093570 · EU 2024-516293-29-01 - 1. fázisNot yet taking people in MagyarországA Study to Assess Adverse Events and How Pivekimab Sunirine Moves Through the Body of Pediatric Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Where
- Budapest
- Életkor
- Up to 17 év
- People
- 18 worldwide
- Run by
- AbbVie Deutschland GmbH & Co. KG
See details and how to join2024-520125-36-00 - 3. fázisBefejeződöttAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
- Where
- Budapest VIII, Debrecen, Pécs, Szeged
- Életkor
- 18 év and over
- People
- 245 worldwide
- Run by
- Servier Affaires Médicales
See details and how to joinNCT05907057 · EU 2022-501709-11-00